[The effect of antiplatelet therapy on the course of COVID-19]. / Vliyanie antiagregantnoi terapii na techenie COVID-19.

Numerous studies demonstrate that a new coronavirus infection is associated with an increased risk of thrombosis, which underlies many of the complications of COVID-19. At the same time, many elderly patients with COVID-19 and with concomitant cordial pathology receive antiplatelet therapy to prevent recurrent ischemic events. The aim of this systematic review was to assess the effect of antiplatelet therapy on the risk of thrombotic complications and disease course in SARS-COV-2 infected patients. We carried out the search of the articles published from 2019 to 2021 with the keywords «antiplatelet therapy¼ and «COVID-19¼ in the PubMed database. A total of 209 articles were retrieved out of which 16 which were included in the review. According to majority of retrospective studies (7 out of 10 studies, more than 30.000 patients), antiplatelet therapy is associated with a statistically significant and prominent reduction in overall mortality. Several studies showed that antiplatelet therapy positively influences the risks of severe respiratory disorders, need of invasive lung ventilation and decreases the probability of thrombotic events. However the only prospective randomized placebo-controlled study did not show a benefit of antiplatelet therapy in symptomatic patients with mild stable COPD-19. None of the studies reported a negative effect of antiplatelet therapy on the course of a new coronavirus infection. Therefore, to date there is no conclusive evidence based on prospective randomized trials, of a positive effect of antiplatelet therapy on the course of COVID-19. Further research on this issue using the double-blind method is needed. However, there are no reports of significant adverse effects of antiplatelet agents, who have previously been given antiplatelet therapy for secondary prevention.

[Current issues of treatment and rehabilitation of patients with neurological disorders and the consequences of COVID-19. Resolution of Advisory Board]. / Osnovnye napravleniya lecheniya i reabilitatsii nevrologicheskikh proyavlenii COVID-19. Rezolyutsiya soveta ekspertov.

Last year the global medical community faced the pandemic of the new coronavirus infection caused by SARS-CoV-2. To date, there is considerable expert experience, which indicates that the brain, along with the corresponding respiratory system, is a target organ for a new coronavirus infection. Moreover, a number of symptoms from the central and peripheral nervous system can persist for several weeks, months, and even tens of months. To designate such protracted clinical conditions, a new definition was introduced: «Post-COVID-19 Condition¼. Advisory Board of Neurologists and Rehabilitation Therapists met to, discuss of practical experience and taking into account scientific information about COVID-19, which was available at the time of the meeting, to develop unified approaches for the management of patients with neurological complications and the consequences of a new coronavirus infection. The Advisory Board worked out a resolution in which formulated the tactics of managing patients with neurological manifestations of COVID-19. The substantiation of the importance and expediency of the development and implementation of a special program of clinical examination of patients who have undergone COVID-19, which would include a clinical examination with a detailed assessment of cognitive functions to early identification and diagnosis of neurodegeneration and subsequent therapy, is given.

Predicting the dynamics of the coronavirus (COVID-19) epidemic based on the case-based reasoning approach

The case-based rate reasoning (CBRR) method is presented for predicting future values of the coronavirus epidemic's main parameters in Russia, which makes it possible to build short-term forecasts based on analogues of the percentage growth dynamics in other countries. A new heuristic method for estimating the duration of the transition process of the percentage increase between specified levels is described, taking into account information about the dynamics of epidemiological processes in countries of the spreading chain. The CBRR software module has been developed in the MATLAB environment, which implements the proposed approach and intelligent proprietary algorithms for constructing trajectories of predicted epidemic indicators.